|
Frequencies of contralateral breast cancer patients CBC carrying apathogenic DNA-damage repair pathway mutation |
||||||||||
| Parameter |
Breast cancer < 50 yearsa (percentage) |
All CBC patients (n = 247) |
Previous RT (n = 169) |
No RT (n = 78) |
Carriers versus non-carriers |
|||||
| n |
Percentage |
n |
Percentage |
n |
Percentage |
OR for CBC after RT |
95% CI |
p |
||
|
|
||||||||||
| DDRP mutated |
~10 |
51 |
21 |
41 |
24.3 |
10 |
12.8 |
2.18 |
1.03–4.62 |
0.043 |
| CHEK2 |
1–2 |
15 |
6.1 |
13 |
7.7 |
2 |
2.6 |
3.17 |
0.69–14.39 |
|
| BRCA1 |
~4–5 |
27 |
11.3 |
20 |
11.8 |
7 |
9 |
1.36 |
0.55–3.37 |
|
| BRCA2 |
~0.5–1 |
5 |
2 |
4 |
2.4 |
1 |
1.3 |
1.87 |
0.21–16.98 |
|
| ATM truncating |
~1–2 |
4 |
1.6 |
4 |
2.4 |
0 |
0 |
- |
- |
|
| 1b |
1.3 |
1.87 |
0.21–16.98 |
|||||||
|
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-damage repair pathway; RT, radiation treatment. aPublished results; bHypothetical assumption of one case. | ||||||||||
Broeks et al. Breast Cancer Research 2007 9:R26 doi:10.1186/bcr1668 |
||||||||||